Bionano Genomics Symposium to feature OGM Presentations and Live Panel Discussion

Bionano Genomics, Inc. provider of optical genome mapping solutions on the Saphyr system as well as the leading software for genomic data visualisation, interpretation, and reporting, announced its 2022 Symposium. 

FREMONT, CA: The 2022 Symposium has been declared by Bionano Genomics, a developer of optical genome mapping (OGM) solutions for the Saphyr system as well as the leading software for genomic data visualization, interpretation, and reporting.  It intends to feature four days of OGM presentations from 25 different customers across the globe on a variety of genetic diseases and cancer applications. From January 10 to 13, 2022, the Symposium will be hosted virtually. Customers are to present their newest research discoveries employing OGM in constitutional cytogenetics, hematologic malignancies, solid tumours, and in combination with next-generation sequencing during these four days (NGS). Within the virtual exhibition hall, each day will have oral client presentations, a live panel with Q&A, and a scientific poster show.

With over 4,500 registered guests, last year's Symposium was a watershed moment for Bionano, highlighting the applicability of OGM for constitutional and cancer cytogenetics applications. The 2022 Symposium, according to Bionano, is expected to be more impactful, with a wider range of applications covered and a day of presentations dedicated to demonstrating the benefits of combining OGM and NGS, which is likely to provide a comprehensive analysis of the genome from single-base variants to full chromosomes.

Bionano Genomics aims to change the way the world views genome sequencing. The symposium is a platform for the OGM community to describe its utility and how it can be coupled with other genome analysis techniques to reveal more answers for hereditary illness and cancer research applications.

Customers around the world have made tremendous progress with the implementation of the Saphyr system across a broad range of clinical research applications for consolidating traditional cytogenetics workflows to OGM as well as demonstrating its utility in combination with NGS since the last Symposium. Symposium attendees have the opportunity to learn from their peers and will continue to provide training, information, and services to clients to achieve our objective of making OGM the standard of care.

The Company also offers an industry-leading, platform-agnostic software solution through its BioDiscovery business that integrates next-generation sequencing and genomic data to provide analysis, visualization, interpretation, and reporting of copy number variants, single-nucleotide variants, and the absence of heterozygosity across the genome in a single consolidated view.